Navigation Links
Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014
Date:7/31/2014

ent of metastatic breast cancer and is also in Phase 2 studies for the treatment of lung and brain cancers. In anti-infectives, Amikacin Inhale is in Phase 3 studies conducted by Bayer Healthcare as an adjunctive treatment for intubated and mechanically ventilated patients with Gram-negative pneumonia. Additional late-stage development products that leverage Nektar's proprietary technology platform include Baxter's BAX 855, a longer-acting rFVIII program, which is in Phase 3 clinical development for patients with hemophilia A.

Nektar's technology has enabled eight approved products in the U.S. or Europe through partnerships with leading biopharmaceutical companies, including UCB's Cimzia® for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS® for hepatitis C and Amgen's Neulasta® for neutropenia.

Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com

*Sources: Bell TJ et. al. Pain Med 2009;10(1):35-42, Hess B et. al. Eur J Intern Med 2011;22(5):527-531, Rosti G et. al Eur Rev Med Pharmacol Sci. 2010;14(12):1045-1050. Galvez R et. al. Aten Primaria 2014;46(1):32-39, Droney J et. al. Support Care Cancer 2008;16(5):453-459.

Movantik is a trademark of AstraZeneca.

Cautionary Note Regarding Forward-Looking StatementsThis press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "expect," "believe," "should," "may," "will" and similar references to future periods. Examples of forward-looking statements include, among others, statements we make regarding the potential regulatory approval of Movantik&
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. Nektar to Announce Financial Results for the Second Quarter 2014 on Thursday, July 31, 2014, After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA
3. Nektar Therapeutics Reports Financial Results for the Third Quarter of 2013
4. Nektar to Announce Financial Results for the Third Quarter of 2013 on Thursday, November 7, 2013, After Close of U.S.-Based Financial Markets
5. Nektar Reports that Partner AstraZeneca Announced European Medicines Agency Acceptance of Marketing Authorisation Application for Naloxegol
6. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2013
7. Nektar to Announce Financial Results for the Second Quarter of 2013 on Thursday, August 8, 2013, After Close of U.S.-Based Financial Markets
8. Nektar Completes Enrollment in Phase 3 BEACON Study of Etirinotecan Pegol in Women With Metastatic Breast Cancer
9. Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence
10. Nektar Presents Positive Preclinical Data for NKTR-214, a Novel Cancer Immunotherapy, At the 2013 American Society of Clinical Oncology Annual Meeting
11. Nektar Presents Target-Specific Biomarkers Being Assessed in Ongoing Phase 3 BEACON Study of Etirinotecan Pegol for the Treatment of Metastatic Breast Cancer at the 2013 American Society of Clinical Oncology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... 2014 , La tecnología ... ensayos clínicos satisfagan el creciente rigor de las autoridades ... los expedientes permanentes de ensayo (TMF, por sus siglas ... TMF en el sector de las ciencias biológicas hasta ... patrocinadores de ensayos clínicos que planean proporcionar a los ...
(Date:9/22/2014)... September 23, 2014 ... Fernzugriffe auf eTMF im Jahr 2015 verdoppeln ... Sponsoren von klinischen Versuchsreihen, die zunehmenden Anforderungen ... von Stammdateien mit Informationen über ihre Versuchsreihen ...     Die bisher größte TMF-Umfrage ...
(Date:9/22/2014)... BARCELONA, Spain , September 23, 2014 ... sponsors to meet health authorities, increasing rigor for trial ... The life sciences industry,s largest TMF survey to date ... sponsors that plan to provide auditors with remote access ... 32% of TMF owners surveyed in the ...
Breaking Medicine Technology:El acceso remoto al eTMF se duplicará en 2015, revela una encuesta general del sector 2El acceso remoto al eTMF se duplicará en 2015, revela una encuesta general del sector 3El acceso remoto al eTMF se duplicará en 2015, revela una encuesta general del sector 4El acceso remoto al eTMF se duplicará en 2015, revela una encuesta general del sector 5Branchenweite Umfrage zeigt, dass sich Fernzugriffe auf eTMF im Jahr 2015 verdoppeln werden 2Branchenweite Umfrage zeigt, dass sich Fernzugriffe auf eTMF im Jahr 2015 verdoppeln werden 3Branchenweite Umfrage zeigt, dass sich Fernzugriffe auf eTMF im Jahr 2015 verdoppeln werden 4Branchenweite Umfrage zeigt, dass sich Fernzugriffe auf eTMF im Jahr 2015 verdoppeln werden 5Remote eTMF Access to Double in 2015, Reveals Industry-wide Survey 2Remote eTMF Access to Double in 2015, Reveals Industry-wide Survey 3Remote eTMF Access to Double in 2015, Reveals Industry-wide Survey 4
... YORK, May 22, 2012  Fox Insurance Company, a Medicare ... announces the confirmation of a judgment in the arbitration ... manager, in excess of $3.3 million, following a suit ... breach of contract.  On May 21, 2012, the U.S. ...
Denmark...
Cached Medicine Technology:Judge Upholds $3.3 Million Judgment In Favor of Fox Insurance Company Against Former Pharmacy Benefit Manager 2
(Date:9/22/2014)... September 23, 2014 Aging skin ... Sublime Beauty® cream helps to relax wrinkles with ... levels and hydrate beautifully. , "Our signature ... for aging skin," says Kathy Heshelow, founder of ... natural botox, wrinkles are relaxed while ingredients boost ...
(Date:9/22/2014)... The Gesundheit! Institute founded by Patch Adams, ... for their existing website. The Institute had outgrown their previous ... to navigate to the different branches of the organization in ... and feel of the site in a more fun and ... graduated from The Medical School of Virginia, he began The ...
(Date:9/22/2014)... (PRWEB) September 23, 2014 Vida ... of a Strategic Alliance Agreement with Florida-based AltMed ... on research, quality assurance, and technical expertise. They’ll ... strengths in their respective markets. , "We’re deeply ... designed into the Vida Cannabis team as they work ...
(Date:9/22/2014)... The leather seat covers offered by Lseat.com ... professional design team to meet customers’ specific product needs and ... of Jeep leather seat covers . Furthermore, the firm ... Each product in the new range is now available at ... the new items are produced, the company’s top designers also ...
(Date:9/22/2014)... September 23, 2014 Recently, BamboofloorChina.com, an ... new range of solid bamboo floors . According ... are now provided at discounted rates, up to 30 ... until September 30. , BamboofloorChina.com is ... solid bamboo floors are made according to the newest ...
Breaking Medicine News(10 mins):Health News:How to Reduce Wrinkles and Improve Aging Skin from Sublime Beauty®; One Day Sale on Now 2Health News:Idea Marketing Group Launches a New Website for The Gesundheit! Institute 2Health News:Idea Marketing Group Launches a New Website for The Gesundheit! Institute 3Health News:Vida Cannabis Allies with Florida Medical Cannabis Leader AltMed to Build Best-in-Class Expertise 2Health News:Great 2007-2012 Jeep Wrangler JK Real Leather Seat Covers Introduced by Lseat.com 2Health News:Cheap Solid Bamboo Floors From Outstanding Online Supplier BamboofloorChina.com 2
... strongly propose that diabetes newly diagnosed in people above ... pancreatic cancer.// Older patients whose diabetes began late in ... with pancreatic cancer within three years following onset of ... people in their 70s when diabetes first appeared. ...
... men are putting their lives at risk because they fail ... embarrassed to consult their general practitioner if they feel a ... case study involving a young man who was involved ... days later he died of a blood clot in the ...
... The functioning of stem cells has an outstanding nature. Initially, ... cells, promising repair of damaged lung tissue. The potential of ... more specialised cells - is now well established.// Researchers at ... first creation of lung cells from stem cells in mice. ...
... at the Hopkins University, working with yeast have ... the replication of HIV inside cells, a finding that ... for the virus that causes AIDS.//,A team of researchers ... virus depends on an enzyme called reverse transcriptase to ...
... new study taking cholesterol-lowering drugs called 'statins' could elevate ... research has shown the benefits of statins, drugs that ... that the drugs might// increase their risk of peripheral ... in the hands and feet. ,The research team ...
... hearing loss are going down well with those who use ... aged over 60 in the United States. Traditionally there was ... acoustic hearing aid. // ,Now, however, there's another choice ... the surrounding bones. Researchers in the US have surveyed 100 ...
Cached Medicine News:Health News:Pancreatic Cancer may be linked to Diabetes 2Health News:Patients with testicular cancer dying through unfamiliarity 2Health News:Elevating Manganese Levels hold back HIV 2
... Human Insulin-like growth factor binding protein-2 ... (further IGFBPs have been proposed) which specifically ... and IGF-II. The binding affinity of IGFBP-2 ... higher than for IGF-I [1], suggesting a ...
... Insulin-like growth factor binding protein-2 (IGFBP-2) is ... have been proposed) which specifically bind and ... The binding affinity of IGFBP-2 for IGF-II ... for IGF-I [1], suggesting a role in ...
... Androstenedione, produced in the adrenal gland and ... testosterone and estrone, both of which may ... relatively weak androgenic activity, estimated at ~(less ... [1]. However, serum androstenedione levels often exceed ...
... proteins that suppress the secretion of FSH ... consists of two distinct chains, or subunits ... consists of the alpha-subunit and betaA-subunit. Inhibin ... Only the dimeric forms of the molecule, ...
Medicine Products: